Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

TELESTA THERAPEUTICS INC T.TST

"Telesta Therapeutics Inc is a biopharmaceutical company. The Company is engaged in the research, development, manufacturing and commercialization of human health products and technologies."


TSX:TST - Post by User

Post by Frogger2on May 30, 2016 3:40pm
369 Views
Post# 24916861

Why would partners pay to keep Montreal operating

Why would partners pay to keep Montreal operatingSince there is not much going on until the company completes a deal I have re-read the last PR from May 10th. There are some interesting comments made that give me the impression that Ipsen will be the merger or sale partner. Half of the $800K per quarter carrying cost could be picked up by existing partners. Makes you wonder why they would do that, why are they interested in that facility being operational.
Ipsen has to pay their own way for approval in their territories while Telesta is on the hook for Canada and USA which won't happen.
That leaves Ipsen unless Endo wants to cough up some cash.

The Company continues to identify and implement opportunities to reduce ongoing operating expenditures and estimates that average cash expenditures for the last quarter of the fiscal year will be less than $0.8 million per month. Almost half of these ongoing expenditures are related to the Company's Montreal MCNA manufacturing facility, and the Company expects that responsibility for these costs will be taken up by its MCNA development partners.
<< Previous
Bullboard Posts
Next >>